The economic burden of psoriasis: A systematic literature review

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 5, 2014, Pages 685-705

  Feldman, Steven R ^a   Burudpakdee, Chakkarin ^b   Gala, Smeet ^b   Nanavaty, Merena ^b   Mallya, Usha G ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MKTXS   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

cost of illness; economic burden; healthcare costs; psoriasis; systematic literature review

Indexed keywords

AUSTRALIA; CANADA; COMORBIDITY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE SEVERITY; GEOGRAPHIC DISTRIBUTION; GERMANY; HOSPITAL COST; HUMAN; ISRAEL; ITALY; NETHERLANDS; POPULATION RESEARCH; PSORIASIS; RESOURCE MANAGEMENT; REVIEW; SPAIN; SWEDEN; SWITZERLAND; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES; ECONOMICS; HEALTH CARE COST; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84907055575     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.933671     Document Type: Review

References (58)

1. National Institutes of Health: National Institute of Arthritis and Musculoskeletal and Skin Diseases. What. is psoriasis? Fast facts: An easy-to-read series of publications for the public. NIH; Bethesda, MD, USA: 2009
2. Langley R, Krueger G, Griffiths C. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(Suppl 2):ii18-23
3. National Psoriasis Foundation Data. 2004. Available from: www.psoriasis.org
4. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 2013; 133(2):377-85
5. Hazard E, Cherry S, Lalla D, et al. Clinical and economic burden of psoriasis. Manage Care Interface 2006;19(4):20-6
6. Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007;57(6):963-71
7. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004: A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006;55(3):490-500
8. Cancer Trends Progress Report - 2007 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD. 2007. Available from: http://progressreport.cancer. gov
9. Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008;4(2):559
10. Fourcade RO, Benedict A, Black LK, et al. BJU Int 2010;105(1):49-56
11. Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol 2012;51(12):1432-40
12. Ismaila AS, Sayani AP, Marin M, Su Z. Clinical, economic, and humanistic burden of asthma in Canada: A systematic review. BMC Pulm Med 2013;13(1):70
13. Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004;20(12):1929-36
14. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006;212(2):123-7
15. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41
16. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35
17. Gerdes S, Zahl V, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2009;220(1):38-43
18. Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm 2013;19(8):621-30
19. Feldman S, Evans C, Russell M. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatol Treat 2005;16(1):37-42
20. Raho G, Koleva DM, Garattini L, Naldi L. The Burden of moderate to severe psoriasis. Pharmacoeconomics 2012;30(11):1005-13
21. The Campbell and Cochrane Economics Methods Group (CCEMG), Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre). CCEMG-EPPI-Centre Cost Converter (version 1.4). Available from: http://eppi. ioe.ac.uk/costconversion/default.aspx
22. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. 2011. Available from: http://handbook.cochrane. org/
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med 2009; 151(4):264-9
24. Jenner N, Campbell J, Plunkett A, Marks R . Cost of psoriasis: A study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 2002;43(4): 255-61
25. Carrascosa J, Pujol R, Dauden E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006;20(7):840-5
26. Navarini AA, Laffitte E, Conrad C, et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010;140(5):85
27. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006;213(2):102-10
28. Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009;25(10):2429-38
29. Chan B, Hales B, Shear N, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg 2009;13(4):192-7
30. Berger K, Ehlken B, Kugland B, Augustin M. Cost of illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005;3(7):511-18
31. Sohn S, Schoffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: A multicenter cost-of-illness study. Dermatology 2006;212(2):137-44
32. Schoffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque type psoriasis in Germany: A multi center study. J Dtsch Dermatol Ges 2007;5(3):209-18
33. Driessen R, Bisschops L, Adang E, et al. The economic impact of high need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010;162(6):1324-9
34. Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010;163(4):807-16
35. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005;24(1):52-7
36. Reich K, Wu E, Mulani P, Gupta S. Direct and indirect economic burden of employees with moderate to severe psoriasis. Proceedings of the 68th Annual Meeting, American Academy of Dermatology; 5-9 March 2010; Miami Beach, FL, USA
37. Han C, Lofland JH, Zhao N, Schenkel B. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 2011;10(8):843-50
38. Hankin CS, Feldman SR, Szczotka A, et al. A cost comparison of treatments of moderate to severe psoriasis Drug Benefit Trends. 2005;17:200-14
39. Leonardi C, Sobell J, Crowley J, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open label study. Br J Dermatol 2012;167(3):658-67
40. Lachaine J, Martel M, Langley R, Poulin YP. Health care resource utilization by patients with psoriasis. Proceedings of the 67th Annual Meeting, American Academy of Dermatology; 6-10 March 2009; San Francisco, CA, USA
41. Poulin Y, Langley R, Teixeira HD, et al. Biologics in the treatment of psoriasis: clinical and economic overview. J Cutan Med Surg 2008;13:S49-57
42. Rabinovich M, Fainaru M. Infliximab for the treatment of extensive plaque psoriasis - regulation, cost and reimbursement. Isr Med Assoc J 2003;5(11):817-18
43. Finzi A, Mantovani L, Belisari A. The cost of hospital related care of patients with psoriasis in Italy based on the AISP study. J Eur Acad Dermatol Venereol 2001;15(4): 320-4
44. Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson Å. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study. Eur J Dermatol 2012; 22(2):238-45
45. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46(6):850-60
46. Carter CT, Goren A, Naim A, Martin S. Psoriasis and psoriatic arthritis patient productivity burden in the United States. Proceedings of the 70th Annual Meeting, American Academy of Dermatology; 16-20 March 2012; San Diego, CA, USA
47. Kulkarni A, Balkrishnan R, Camacho F, et al. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs dermatol 2003;3(6):661-6
48. Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatol Treat 2006;17(5):294-301
49. Gunnarsson C, Chen J, Rizzo JA, et al. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatol Treat 2012;23(4):240-54
50. Lin H-C, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatol Treat 2012;23(3): 196-202
51. Rich S, Russell MW, Feldman SR. Estimates of failure rates and direct medical costs associated with the use of systemic treatments and phototherapy in patients with psoriasis. 16th Annual Meeting, Academy of Managed Care Pharmacy; 31 March-3 April 2004; San Francisco, CA, USA
52. Nelson AA, Pearce DJ, Fleischer AB Jr, et al. Infliximab for inpatient psoriasis management-is there a role? J Dermatol Treat 2005;16(5-6):314-18
53. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol 2010;146(1):46-54
54. Association AARD. A briefing report on autoimmune disease and AARDA: past, present and future. American Autoimmune Related Diseases Association; Eastpointe, MI, USA: 2010
55. Hakkaart-van Roijen L, Verboom P, et al. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis. Pharmacoeconomics 2001;19(5): 599-608
56. Schmitt-Egenolf M. Switching biologicals: switching TNFa antagonists in psoriasis treatment. Dermatology 2008;216(4):281-2
57. American Academy of Dermatology. AAD. Available from: www.aad.org/mobilepsoriasis/
58. Cimmino M. Epidemiology of psoriasis and psoriatic arthritis. Reumatismo 2011; 59(Suppl 1):19-24